The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics
Status:
Completed
Trial end date:
2021-05-06
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-dose, Phase 1 study, to assess the effect of
moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan
(ACT-132577).